Analysts Set GoodRx Holdings, Inc. (NASDAQ:GDRX) PT at $8.18

GoodRx Holdings, Inc. (NASDAQ:GDRX) has earned an average rating of “Moderate Buy” from the ten ratings firms that are presently covering the firm, Marketbeat Ratings reports. Three research analysts have rated the stock with a hold recommendation, six have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year target price among analysts that have updated their coverage on the stock in the last year is $8.18.

A number of equities research analysts have commented on the company. KeyCorp decreased their price target on GoodRx from $7.00 to $6.00 and set an “overweight” rating on the stock in a report on Wednesday, January 8th. Morgan Stanley decreased their target price on GoodRx from $7.00 to $6.00 and set an “equal weight” rating on the stock in a research note on Tuesday, December 17th. Citigroup dropped their price target on GoodRx from $7.00 to $6.25 and set a “buy” rating for the company in a research note on Friday, January 10th. Finally, Wells Fargo & Company reduced their price objective on shares of GoodRx from $9.00 to $8.00 and set an “overweight” rating on the stock in a research report on Friday, February 28th.

Institutional Trading of GoodRx

Large investors have recently made changes to their positions in the business. Total Wealth Planning & Management Inc. bought a new stake in GoodRx during the fourth quarter worth approximately $68,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its position in shares of GoodRx by 70.4% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 149,945 shares of the company’s stock valued at $697,000 after purchasing an additional 61,924 shares during the last quarter. Two Sigma Advisers LP raised its holdings in GoodRx by 69.1% during the 4th quarter. Two Sigma Advisers LP now owns 754,000 shares of the company’s stock valued at $3,506,000 after buying an additional 308,000 shares during the period. Two Sigma Investments LP lifted its position in GoodRx by 98.1% in the fourth quarter. Two Sigma Investments LP now owns 722,374 shares of the company’s stock worth $3,359,000 after buying an additional 357,674 shares during the last quarter. Finally, State of Wyoming boosted its stake in GoodRx by 76.2% during the fourth quarter. State of Wyoming now owns 67,290 shares of the company’s stock worth $313,000 after buying an additional 29,100 shares during the period. 63.77% of the stock is currently owned by institutional investors.

GoodRx Stock Performance

Shares of NASDAQ GDRX opened at $4.01 on Tuesday. The company has a debt-to-equity ratio of 0.70, a current ratio of 5.48 and a quick ratio of 5.48. GoodRx has a 1 year low of $3.82 and a 1 year high of $9.26. The firm has a fifty day moving average price of $4.71 and a 200-day moving average price of $5.14. The stock has a market cap of $1.54 billion, a PE ratio of -133.67, a price-to-earnings-growth ratio of 2.46 and a beta of 1.25.

GoodRx Company Profile

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.